Published in Ann Surg on August 01, 1996
Hepatic Retransplantation--an analysis of risk factors associated with outcome. Transplantation (1996) 1.22
Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg (2002) 1.22
Preoperative assessment of risk in liver transplantation: a multivariate analysis in 2376 cases of the UW era. Transplant Proc (1997) 0.79
Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation (1998) 0.79
ABO-compatible liver allograft antibody-mediated rejection: an update. Curr Opin Organ Transplant (2015) 0.78
Preoperative selective desensitization of live donor liver transplant recipients considering the degree of T lymphocyte cross-match titer, model for end-stage liver disease score, and graft liver volume. J Korean Med Sci (2014) 0.75
The effect of a positive T-lymphocytotoxic crossmatch on clinical outcomes in adult-to-adult living donor liver transplantation. J Korean Surg Soc (2013) 0.75
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19
Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet (1966) 5.54
Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53
Significance of the positive crossmatch test in kidney transplantation. N Engl J Med (1969) 5.50
A simple micro cytotoxicity test. Transplantation (1969) 3.67
Successful liver transplantation from crossmatch-positive donors. Transplant Proc (1981) 2.80
Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology (1994) 2.73
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Liver transplantation across ABO blood groups. Surgery (1986) 2.39
Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
Risk factors for primary dysfunction after liver transplantation--a multivariate analysis. Transplantation (1993) 2.20
Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med (1994) 1.92
The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83
Effect of cold ischemia time on the early outcome of human hepatic allografts preserved with UW solution. Transplantation (1991) 1.71
HLA compatibility and liver transplant outcome. Improved patient survival by HLA and cross-matching. Transplantation (1994) 1.71
Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. Transplantation (1992) 1.68
Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation. Lancet (1987) 1.68
DTT test: a new method to differentiate IgM and IgG erythrocyte antibodies. Vox Sang (1974) 1.59
A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology (1992) 1.50
Ischemic-type biliary complications after orthotopic liver transplantation. Hepatology (1992) 1.46
Successful transplantation after conversion of a positive crossmatch to negative by dissociation of IgM antibody. Transplantation (1989) 1.46
Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol (1988) 1.45
Single-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression. Ann Surg (1994) 1.33
Effect of donor age and sex on the outcome of liver transplantation. Hepatology (1995) 1.31
Liver transplantation across ABO blood group barriers. Lancet (1990) 1.29
Donor species complement after liver xenotransplantation. The mechanism of protection from hyperacute rejection. Transplantation (1994) 1.21
Predictive factors of early postoperative graft function in human liver transplantation. Hepatology (1994) 1.16
The use of "marginal" donors for organ transplantation. The influence of donor age on outcome. Transplantation (1991) 1.05
The successful use of older donors for liver transplantation. JAMA (1989) 0.95
The use of older donor livers for hepatic transplantation. Transplantation (1990) 0.92
Significance of a positive crossmatch on outcome in human liver transplantation. Transplant Proc (1992) 0.89
HLA alloimmunization and blood requirements in orthotopic liver transplantation. Transplant Proc (1989) 0.87
Probable antibody-mediated failure of two sequential ABO-compatible hepatic allografts in a single recipient. Transplantation (1993) 0.87
Outcome of liver transplantation using donors 60 to 79 years of age. Transplant Proc (1995) 0.85
AHG and DTE/AHG procedure identification of crossmatch-appropriate donor-recipient pairings that result in improved graft survival. Transplantation (1991) 0.85
Detection of alloantibodies using a sensitive antiglobulin microcytotoxicity test: identification of low levels of pre-formed antibodies in accelerated allograft rejection. Tissue Antigens (1972) 0.84
Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. Transplantation (1995) 0.83
FK506 conversion for intractable rejection of the liver allograft. Transpl Int (1993) 0.82
The lack of long-term detrimental effects on liver allografts caused by donor-specific anti-HLA antibodies. Transplantation (1993) 0.81
Positive pretransplant crossmatches predict early graft loss in liver allograft recipients. Transplantation (1994) 0.80
Importance of donor blood chemistry data (AST, serum sodium) in predicting liver transplant outcome. Transplant Proc (1991) 0.79
A prospective study of the clinical relevance of the current serum antiglobulin-augmented T cell crossmatch in renal transplant recipients. Transplant Proc (1987) 0.77
OKT3 therapy as a cause of high panel-reactive antibodies in serum using standard microcytotoxicity techniques. Transplantation (1988) 0.76
The importance of serum dithiothreitol treatment in crossmatching selection of presensitized kidney transplant recipients. Transplantation (1990) 0.76
Evolution of liver transplantation. Hepatology (1982) 19.54
A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33
Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11
The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40
The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24
Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19
Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04
Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95
The portal circulation: I. The action of adrenaline and pituitary pressor extract. J Physiol (1932) 6.88
Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64
Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53
Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44
Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24
Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12
Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08
Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08
Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99
Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99
Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91
The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84
Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66
Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Hepatic Retransplantation. Transplant Proc (1985) 3.62
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49
Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38
The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Delayed biliary duct obstruction after orthotopic liver transplantation. Surgery (1972) 3.26
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Changes in blood coagulation. Arch Surg (1966) 3.22
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Renal transplantation in baboons under FK 506. Surgery (1989) 3.17
Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg (1985) 3.17
Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16
Liver transplantation before 1 year of age. J Pediatr (1987) 3.15
In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
The human HOX gene family. Nucleic Acids Res (1989) 3.13
Fungal infections in liver transplant recipients. Transplantation (1985) 3.07
De novo malignant tumors in organ transplant recipients. Transplant Proc (1971) 3.03
Experience with 150 liver resections. Ann Surg (1983) 3.01
A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01
Chronic survival after human renal homotransplantation. Lymphocyte-antigen matching, pathology and influence of thymectomy. Ann Surg (1965) 3.00
Death after transplantation; an analysis of sixty cases. Am J Med (1967) 2.99
Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98
Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Iatrogenic alterations of immunologic surveillance in man and their influence on malignancy. Transplant Rev (1971) 2.94
Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet (1981) 2.92
Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet (1984) 2.91
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Liver transplantation in adults. Hepatology (1982) 2.89
Veno-venous bypass without systemic anticoagulation for transplantation of the human liver. Surg Gynecol Obstet (1985) 2.88
Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Successful liver transplantation from crossmatch-positive donors. Transplant Proc (1981) 2.80
Studies of homograft sex and of gamma globulin phenotypes after orthotopic homotransplantation of the human liver. Surg Forum (1969) 2.80
The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79
Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis (1988) 2.76
Clinical reactions and serologic changes after the administration of heterologous antilymphocyte globulin to human recipients of renal homografts. Ann Intern Med (1968) 2.72
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
Mechanism and modification of rejection of heterografts between divergent species. Transplant Proc (1970) 2.63
A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62
Growth-stimulating factor in regenerating canine liver. Lancet (1979) 2.61
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Portal vein grafts in hepatic transplantation. Surg Gynecol Obstet (1985) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
Studies of blood flow and ultrastructural changes in rejecting and nonrejecting canine orthotopic liver homografts. Surgery (1968) 2.58